Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

#4356

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Aim(s): Evaluate the long-term (24 months) impact of Lu-177-oxodotreotide treatment, assessing the appearance and evolution of side effects.

Materials and methods: A retrospective observational study of patients treated with 4 cycles (7.4 GBq) of Lu-177 since 2018, with a follow-up of 24 months. Patients who died before this period or did not complete the treatment were excluded. Systematic analyses were conducted to assess impacts on radiosensitive organs, especially kidneys and bone marrow.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,